X4 Pharmaceuticals, Inc. (XFOR): Price and Financial Metrics
GET POWR RATINGS... FREE!
XFOR Stock Price Chart Interactive Chart >
XFOR Price/Volume Stats
| Current price | $1.00 | 52-week high | $2.41 |
| Prev. close | $1.04 | 52-week low | $0.65 |
| Day low | $0.99 | Volume | 421,283 |
| Day high | $1.04 | Avg. volume | 805,716 |
| 50-day MA | $1.08 | Dividend yield | N/A |
| 200-day MA | $1.28 | Market Cap | 69.03M |
X4 Pharmaceuticals, Inc. (XFOR) Company Bio
X4 Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company specializes in developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases including primary immunodeficiencies and cancer. X4's oral small molecule drug candidates antagonize the CXCR4 pathway which plays a central role in immune surveillance.
Latest XFOR News From Around the Web
Below are the latest news stories about X4 PHARMACEUTICALS INC that investors may wish to consider to help them evaluate XFOR as an investment opportunity.
X4 Pharmaceuticals Inc. (XFOR) can excel with these strategiesIn Friday’s session, X4 Pharmaceuticals Inc. (NASDAQ:XFOR) marked $0.93 per share, down from $0.99 in the previous session. While X4 Pharmaceuticals Inc. has underperformed by -6.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, XFOR fell by -76.21%, with highs and lows ranging from $4.20 to […] |
X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic NeutropeniaOral presentation further details positive data from mavorixafor Phase 1b clinical trial in people with chronic idiopathic, cyclic, or congenital neutropenia Medical claims research defines an estimated 50,000 U.S. chronic neutropenia patient population; patient survey voices the significant unmet medical needs BOSTON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases |
Looking For A Top Momentum Stock? Check Out X4 Pharmaceuticals Inc. (NASDAQ: XFOR)X4 Pharmaceuticals Inc. (NASDAQ:XFOR) shares, rose in value on Friday, 12/09/22, with the stock price down by -6.06% to the previous day’s close as strong demand from buyers drove the stock to $0.93. Actively observing the price movement in the last trading, the stock closed the session at $0.99, falling within a range of $0.9157 … Looking For A Top Momentum Stock? Check Out X4 Pharmaceuticals Inc. (NASDAQ: XFOR) Read More » |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for another dive into the biggest pre-market stock movers as we check out the latest news traders need to know about on Wednesday! |
X4 Pharmaceuticals stock dips after pricing $65M securities offering (NASDAQ:XFOR)X4 Pharmaceuticals (XFOR) shares fell 9% premarket on Wednesday after the therapeutics firm priced an $65M securities offering.The offering includes 52.3M shares of its common… |
XFOR Price Returns
| 1-mo | -14.53% |
| 3-mo | -44.44% |
| 6-mo | -21.88% |
| 1-year | -45.95% |
| 3-year | -88.69% |
| 5-year | -98.69% |
| YTD | 0.70% |
| 2022 | -56.64% |
| 2021 | -64.39% |
| 2020 | -39.91% |
| 2019 | -23.13% |
| 2018 | -81.82% |
Continue Researching XFOR
Want to see what other sources are saying about X4 Pharmaceuticals Inc's financials and stock price? Try the links below:X4 Pharmaceuticals Inc (XFOR) Stock Price | Nasdaq
X4 Pharmaceuticals Inc (XFOR) Stock Quote, History and News - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...